DARE vs. VTGN, REPH, ABEO, GTHX, GLSI, GALT, RNAC, RZLT, ALIM, and RIGL
Should you be buying Daré Bioscience stock or one of its competitors? The main competitors of Daré Bioscience include Vistagen Therapeutics (VTGN), Recro Pharma (REPH), Abeona Therapeutics (ABEO), G1 Therapeutics (GTHX), Greenwich LifeSciences (GLSI), Galectin Therapeutics (GALT), Cartesian Therapeutics (RNAC), Rezolute (RZLT), Alimera Sciences (ALIM), and Rigel Pharmaceuticals (RIGL). These companies are all part of the "medical" sector.
Daré Bioscience (NASDAQ:DARE) and Vistagen Therapeutics (NASDAQ:VTGN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, community ranking, risk, media sentiment and institutional ownership.
Daré Bioscience received 73 more outperform votes than Vistagen Therapeutics when rated by MarketBeat users. Likewise, 73.29% of users gave Daré Bioscience an outperform vote while only 72.24% of users gave Vistagen Therapeutics an outperform vote.
Daré Bioscience currently has a consensus target price of $4.50, suggesting a potential upside of 997.56%. Vistagen Therapeutics has a consensus target price of $19.00, suggesting a potential upside of 385.93%. Given Daré Bioscience's higher probable upside, analysts plainly believe Daré Bioscience is more favorable than Vistagen Therapeutics.
Daré Bioscience has a net margin of 0.00% compared to Vistagen Therapeutics' net margin of -3,073.51%. Vistagen Therapeutics' return on equity of -72.10% beat Daré Bioscience's return on equity.
Daré Bioscience has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500. Comparatively, Vistagen Therapeutics has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500.
In the previous week, Daré Bioscience had 1 more articles in the media than Vistagen Therapeutics. MarketBeat recorded 4 mentions for Daré Bioscience and 3 mentions for Vistagen Therapeutics. Vistagen Therapeutics' average media sentiment score of 1.25 beat Daré Bioscience's score of 0.66 indicating that Vistagen Therapeutics is being referred to more favorably in the news media.
6.7% of Daré Bioscience shares are owned by institutional investors. Comparatively, 78.4% of Vistagen Therapeutics shares are owned by institutional investors. 4.0% of Daré Bioscience shares are owned by company insiders. Comparatively, 1.0% of Vistagen Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Daré Bioscience has higher revenue and earnings than Vistagen Therapeutics.
Summary
Daré Bioscience beats Vistagen Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Daré Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for DARE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DARE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Daré Bioscience Competitors List
Related Companies and Tools
